Objective To investigate the effects of Jinshuibao on oxidative stress and micro-inflammation state in pa-tients with diabetic nephropathy maintenance hemodialysis. Methods Thirty six diabetic nephropathy patients who had received CHD for over half year in Blood Purification Center of Zhongshan Hospital in Hubei Province were assigned into the control group (18 cases) and the treated group (18 cases). Control group were given conventional hemodialysis for 4 hours, 3 times a week; treatment group were given conventional hemodialysis combined with Jinshuibao Capsules, orally, 0.33 g/grain, once 5 grains, 3 times a day. Both groups were treated for 3 months. Blood was collected before and after treatment for detection of hs-CRP, IL-6, TNF-α, MDA, SOD, GSH-Px levels. Results Compared with the indexes before treatment, in control group, IL-6 [(19.70±1.11) ng/mL vs (23.17±1.76) ng/mL], TNF-α[(50.94±1.52) ng/L vs (55.39±1.87) ng/L], hs-CRP [(8.58±0.67) mg/L vs (10.17±0.42) mg/L], MDA [(5.51±0.33) nmol/L vs (6.59±0.25) nmol/L] were significantly increased (P<0.01) and SOD [(55.19±2.82) nU/mL vs (46.51±1.89) nU/mL], GSH-Px [(197.05±8.88) U/L vs (171.39±7.83) U/L] were significantly declined after treatment (P<0.01);in treatment group, IL-6 [(19.36±1.71) ng/mL vs (14.79±2.95) ng/mL], TNF-α [(51.13±1.42) ng/L vs (45.66±1.74) ng/L], hs-CRP [(8.72±0.85) mg/L vs (6.44±0.95) mg/L], MDA [(5.68±0.58) nmol/L vs (4.81±0.58) nmol/L] were significantly declined (P<0.01), SOD [(54.00±2.42) nU/mL vs (63.90±3.53) nU/mL], GSH-Px [(197.47±8.48) U/L vs (237.77±9.44) U/L] were significantly increased after treatment (P<0.01). There were statistically significant differences between the control group and the treatment group of IL-6, TNF-α, hs-CRP, MDA, SOD, GSH-Px after treatment (all P 约 0.01). Conclusion Micro-inflammation state and oxidative stress exists popularly in diabetic nephropathy maintenance hemodialysis patients. Jinshuibao can aggravate oxidative stress and micro-inflammation state in diabetic nephropathy maintenance hemodialysis patients.%目的：观察金水宝对糖尿病肾病维持性血液透析患者氧化应激及微炎症状态的改善作用。方法选择2013年2~5月湖北省中山医院血液净化中心透析时间超过6个月的36例糖尿病肾病血液透析患者，随机分为对照组（18例）和治疗组（18例）。对照组给予常规碳酸氢盐血液透析治疗，每周3次，每次治疗4 h；治疗组为常规碳酸氢盐血液透析基础上加用金水宝胶囊口服，0.33 g/粒，每次5粒，每日3次。两组均治疗3个月。两组研究对象均于研究开始前及治疗3个月后检测血清超敏C反应蛋白（hs-CRP）、白介素6（IL-6）、肿瘤坏死因子-α（TNF-α）、过氧化物歧化酶（SOD）、谷胱甘肽过氧化物酶（GSH-Px）、丙二醛（MDA）的变化。结果与治疗前比较，对照组患者治疗后IL-6[（19.70±1.11）ng/mL比（23.17±1.76）ng/mL]、TNF-α[（50.94±1.52）ng/L比（55.39±1.87）ng/L]、hs-CRP[（8.58±0.67）mg/L比（10.17±0.42）mg/L]、MDA[（5.51±0.33）nmol/L比6.59±0.25）nmol/L]水平均显著升高（P<0.01），SOD[（55.19±2.82）nU/mL比（46.51±1.89）nU/mL]、GSH-Px[（197.05±8.88）U/L比（171.39±7.83）U/L]显著降低（P<0.01）；治疗组治疗后与治疗前比较，IL-6[（19.36±1.71）ng/mL比（14.79±2.95）ng/mL]、TNF-α[（51.13±1.42）ng/L比（45.66±1.74）ng/L]、hs-CRP[（8.72±0.85）mg/L比（6.44±0.95）mg/L]、MDA[（5.68±0.58）nmol/L比（4.81±0.58）nmol/L]水平均显著降低（P<0.01），SOD [（54.00±2.42）nU/mL比（63.90±3.53）nU/mL]、GSH-Px [（197.47±8.48）U/L比（237.77±9.44）U/L]均显著升高（P<0.01）；两组治疗后IL-6、TNF-α、hs-CRP、MDA、SOD、GSH-Px组间差异有高度统计学意义（P<0.01）。结论糖尿病肾病维持性血液透析患者体内普遍存在氧化应激及微炎症状态，金水宝胶囊可改善糖尿病肾病维持性血液透析患者体内的氧化应激及微炎症状态。
展开▼
